Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial readout, as global demand for the technology increases. The company ...

SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...

Edwards Lifesciences reports strong Q4 2025 results with 13.3% sales growth to $1.57B, driven by TAVR and TMTT performance ...

Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences' Sapien 3 Ultra system. The artificial heart valve is pushed through the blood vessels via a catheter and ...

The heart valve specialist reported a second straight quarter of double-digit TAVR sales growth and credited recent study results with driving a “sense of urgency” for treating patients.

In December, Edwards Lifesciences persuaded CMS to publish an updated tracking sheet for TAVR national coverage analysis, causing the agency to reconsider its previous stance on covering transcatheter ...

Edwards LifesciencesEW stock surged Friday after the medtech giant hiked its 2025 outlook following a key setback for rival Boston ScientificEW. In May, Boston Sci pulled its transcatheter aortic ...

Investors reacted positively to Edwards’ 2026 guidance with shares up 1.25% in after-hours trading following the announcement.

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...